William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses patient factors that predispose them to adverse complications during surgery for ovarian cancer and using those predictors to improve care.
William Cliby, MD, consultant, division of gynecologic surgery, department of obstetrics & gynecology, Mayo Clinic, discusses patient factors that predispose them to adverse complications during surgery for ovarian cancer and using those predictors to improve care.
Transcript
What patient factors would predispose them to adverse complications during surgery for ovarian cancer?
That’s very important. A big part of what we’ve been doing the last 10 or 15 years is identifying the risk factors for serious complications after ovarian cancer surgery. Of course, the importance of surgery in leaving very little residual disease on survival is known and accepted. But, sometimes doing those surgeries are quite complex, and patients can have bad complications as a result. So, we’ve identified that the factors that most predict complications are, again, the patient’s age, performance status, or some measure of their frailty, and then their nutrition level.
Patients that have any of those factors at are negative, they really have a high and probably unacceptably high risk from upfront surgery. So, they’re better served by some other way to address their ovarian cancer, perhaps adding in surgery later in the course of their treatment.
How can you use these predictors to improve quality of care and management of ovarian cancer?
So, for us, it’s about not taking a one size fits all approach. We shouldn’t treat most patients with chemotherapy first and then surgery, and we shouldn’t try to treat all patients with surgery first and then chemotherapy. Using these factors that I mentioned before, patient factors, as well as the treating centers factors, we can triage patients best to what they can tolerate to get them best overall care.
We’re not so focused on just the surgical outcomes. We’ve got a long battle to wage against ovarian cancer that we want to have the best overall outcome.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More